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Objectives This study sought to define contemporary trends in permanent pacemaker use by analyzing a large national
database.
Background The Medicare National Coverage Determination for permanent pacemaker, which emphasized single-chamber
pacing, has not changed significantly since 1985. We sought to define contemporary trends in permanent pace-
maker use by analyzing a large national database.
Methods We queried the Nationwide Inpatient Sample to identify permanent pacemaker implants between 1993 and
2009 using the International Classification of Diseases-Ninth Revision-Clinical Modification procedure codes for
dual-chamber (DDD), single-ventricular (VVI), single-atrial (AAI), or biventricular (BiV) devices. Annual permanent
pacemaker implantation rates and patient demographics were analyzed.
Results Between 1993 and 2009, 2.9 million patients received permanent pacemakers in the United States. Overall use
increased by 55.6%. By 2009, DDD use increased from 62% to 82% (p  0.001), whereas single-chamber ven-
tricular pacemaker use fell from 36% to 14% (p  0.01). Use of DDD devices was higher in urban, nonteaching
hospitals (79%) compared with urban teaching hospitals (76%) and rural hospitals (72%). Patients with private
insurance (83%) more commonly received DDD devices than Medicaid (79%) or Medicare (75%) recipients
(p  0.001). Patient age and Charlson comorbidity index increased over time. Hospital charges ($2011) in-
creased 45.3%, driven by the increased cost of DDD devices.
Conclusions There is a steady growth in the use of permanent pacemakers in the United States. Although DDD device use is
increasing, whereas single-chamber ventricular pacemaker use is decreasing. Patients are becoming older and
have more medical comorbidities. These trends have important health care policy implications. (J Am Coll
Cardiol 2012;60:1540–5) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.017Implantation of cardiac pacemakers in the United States has
increased (1–3). Pacemaker technology has advanced from
fixed-rate single-chamber pacemakers to dual-chamber
pacemakers with pacing algorithms to enhance rate response
and to minimize ventricular pacing. Despite these advance-
ments, the National Coverage Determination for Cardiac
Pacemakers, published by the Centers for Medicare and
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accepted July 2, 2012.Medicaid Services, has not changed significantly since 1985
(4). We evaluated cardiac pacemaker implantation trends in
the United States to assess the disparity between National
Coverage Determination policies, which emphasized the
role of single-chamber pacing, and contemporary medical
practice.
Methods
The Nationwide Inpatient Sample (NIS) was queried to
identify patient demographics, health risk profile, and
health economic data for pacemaker patients between 1993
and 2009 using the International Classification of Diseases-
Ninth Revision-Clinical Modification. The annual NIS is a
statistically valid annual survey of approximately 20% of
hospitalizations in the United States, regardless of payment
source. The type of pacemaker implanted was characterized as
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pacemaker, or biventricular (BiV) pacemaker. For the present
study, we used the International Classification of Diseases-
Ninth Revision-Clinical Modification codes for DDD (37.83),
VVI (37.81–82, 37.71), AAI (37.81–81, 37.73), or BiV
(00.51) devices. Trends for sinus node dysfunction patients
were analyzed using diagnosis codes 427.8 and 427.6.
The severity of comorbidities was characterized by the
Charlson comorbidity index (CCI), which consists of 19
different disease comorbidity categories, weighted to yield a
total score (5). The CCI has previously been validated as a
predictor of mortality in patients with a pacemaker (3).
Statistical analyses of the NIS records with the relevant
surgical codes were conducted using SAS software version
9.2 (SAS Institute, Cary, North Carolina). Hospital charges
for the study period were adjusted to the equivalent amount
in January 2011 using the consumer price index for medical
services published by the Bureau of Labor Statistics. The
sampling weights and the stratified sampling design of the
NIS were taken into consideration when computing sum-
mary statistics and standard errors of these estimates. The
number of surgeries performed for a particular demographic
group is a positive integer and is assumed to follow a
Poisson distribution. A regression model was used to
estimate the surgery rate and was normalized by the size of
the population and by evaluation of the calendar year trend.
The surgery rate was adjusted by age, sex, race, and census
regions to accommodate differences in the prevalence
among demographic subpopulations. The patient health
profile was calculated for each year, and linear regression
was used to test for changes over time. The type of hospital
Figure 1 Pacemaker Use in the United States From 1993 Thro
The rate of dual-chamber pacemaker implantation (number of implants/100,000 p
Biventricular pacemakers, introduced in 2002, have leveled off after their initial inperforming pacemaker surgery
was divided into urban non-
teaching, urban teaching, and ru-
ral. The distribution of pace-
maker surgery was analyzed for
both type of hospital and type of
insurance (private vs. Medicaid
vs. Medicare).
Results
Between 1993 and 2009, 2.9 mil-
lion patients received a perma-
nent pacemaker in the United
States. During this time, overall
use increased by 55.6%, from
121,300 in 1993 to 188,700 in 2009. This represents 46.7
implantations per 100,000 persons in 1993, which increased
to 61.6 implantations per 100,000 persons in 2009 (Fig. 1).
lthough DDD pacemakers increased annually from 29.1/
00,000 to 50.4/100,000 (p  0.0001), VVI pacemakers
ecreased from 17.2/100,000 to 8.7/100,000 (p  0.01). By
009, DDD use increased from 62% to 82% of all implants
p  0.001), while VVI use decreased from 36% to 14% (p
0.01). Although AAI use remained constant at 1%, BiV
acemaker use increased to 4% in 2009 from a base in 2001.
emographic trends. The impact of gender on pacemaker
se was analyzed. During the study period, DDD pacemak-
rs were implanted in 77.3% of men, whereas 20.1%
eceived VVI pacemakers, 0.5% received AAI pacemakers,
nd 1.9% received BiV pacemakers. By contrast, 76.8% of
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s) has increased over time until 2001, when use reached a plateau.
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Trends in Permanent Pacemaker Implantation October 16, 2012:1540–5women received DDD pacemakers, whereas 21% received
VVI pacemakers, 0.6% received AAI pacemakers, and 0.6%
received BiV pacemakers.
The mean age at implantation increased over time
(Fig. 2). Those receiving VVI pacemakers were older than
DDD patients (p  0.0001). In 1993, DDD patients
veraged 73.3 years of age, which increased to 75.4 years of
ge in 2009 (p  0.0001). By contrast, in 1993, VVI
atients were 77.5 years of age, which increased to 80.1
ears of age in 2009 (p  0.0001). The BiV patients also
ncreased in age from 71.8 years in 2002 to 74.7 years in
009 (p  0.0001).
rends based on type of hospital and insurance. The
nfluence of hospital location was analyzed by evaluating
acemaker use in rural hospitals, urban nonteaching hospi-
als, and urban teaching hospitals. The use of DDD devices
as higher in urban nonteaching hospitals (79%) compared
ith urban teaching hospitals (76%) and rural hospitals
73%), (p  0.01). Patients with private insurance (83%)
ore commonly received DDD devices than Medicaid
79%) or Medicare (75%) patients (p  0.001). To analyze
urther the impact of insurance type, the use of DDD
acemakers was evaluated after adjusting for factors such as
ge, sex, race, calendar year, urban or rural hospital location,
nd hospital size. After controlling for these factors, Medicaid
atients were less likely than Medicare patients (hazard ratio:
.84, 95% confidence interval: 0.79 to 0.886, p  0.001),
hereas private insurance patients were more likely than
edicare patients (hazard ratio: 1.205, 95% confidence inter-
al: 1.165 to 1.247, p  0.001) to receive DDD pacemakers.
rends in patient comorbid conditions. Patient comor-
idities were analyzed by measuring the average CCI for
ach calendar year. The patient level of comorbidity in-
reased over time for all types of pacemakers. In 1993, the
Figure 2 Age of Pacemaker Patients at Time of Implantation
The average age of pacemaker patients has increased slowly over time. Patients waverage CCI was 0.6  0.9 for DDD patients versus 0.6 
.0 for VVI patients. By contrast, in 2009, DDD patients
ad a CCI of 1.5  1.5, whereas VVI patients had a CCI
f 1.6  1.6. The complexity of the patient’s condition was
easured by determining the number of patients with a
CI of more than 2. In 1993, a CCI of more than was 2
resent in 14.1% of VVI patients, which increased to 45.1%
n 2009. A similar trend was seen in the DDD group. In
993, 13.5% of patients had a CCI of more than 2, which
ncreased to 42.4% in 2009.
acemaker implantation trends in patients with sinus
ode dysfunction. We evaluated the impact of the diag-
osis of sick sinus dysfunction on device use by analyzing
acemaker patients with codes 427.81 (sick sinus syndrome)
nd 426.6 (sinoatrial block) (Fig. 3). In this subgroup,
DD use increased, whereas VVI use decreased. By 2009,
ore than 80% of patients with sinus node dysfunction
eceived a DDD pacemaker. Therefore, the diagnosis of
inus node dysfunction did not seem to have an impact on
he type of device implanted.
conomic trends in pacemaker implantation. We que-
ied the NIS to determine hospital charges associated with
acemaker insertion as an indicator of economic cost. Total
ospital charges associated with pacemaker procedures in-
reased during the study period (Fig. 4). Hospital charges in
011 dollars increased by 45.3% from $53,693 in 1993 to
78,015 in 2009.
iscussion
he major findings of this analysis of a large national
atabase are: 1) permanent pacemaker implantations in the
nited States have increased; 2) use plateaued in 2001;
) use of dual-chamber pacemakers increased, whereas that
gle-ventricular pacemakers are older than those with dual-chamber pacemakers.ith sin
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October 16, 2012:1540–5 Trends in Permanent Pacemaker Implantationof single-chamber VVI pacemakers decreased, and DDD
pacemakers now represent more than 80% of all pacemaker
implantations; 4) pacemaker patients are becoming older
and have a greater number of medical comorbidities; 5) use
was impacted by the type of hospital and health insurance;
and 6) these trends had financial implications as hospital
charges increased.
Figure 3 Use of Pacemakers in Patients Paced for Sinus Node
The distribution of pacemaker type in patients paced for sinus node dysfunction is
Figure 4 Hospital Charges Associated With Permanent Pacema
The hospital charges associated with pacemaker implantation have increased oveTrends in permanent pacemaker implantation. There
has been an increase in the annual pacemaker implantation
rate (number of implants/100,000 persons) since 1993.
However, this rate has plateaued since 2001. The 2005
World Survey of Cardiac Pacing confirmed this trend,
finding that new implants in the United States were 786 per
million in 2001 and 752 per 1 million in 2005 (2). Our
nction
r to that of the group as a whole.
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Trends in Permanent Pacemaker Implantation October 16, 2012:1540–5previous study showed that overall pacemaker implantation
peaked in 2001, whereas the overall use of cardiac implant-
able electronic devices continued to increase through 2006,
driven by the marked increase in implantable cardioverter
defibrillators implantation and introduction of cardiac re-
synchronization therapy (1).
Use of dual-chamber pacemakers. Dual-chamber tech-
nology has been adopted as the technology of choice in the
United States. This technology represents an advance over
single-chamber ventricular demand pacemakers. Current
DDD pacemakers provide bradycardia support at the lower
rate limit, while maintaining AV synchrony, as well as rate
responsiveness at faster heart rates by tracking the intrinsic
P wave. At the same time, current pacemaker algorithms
minimize ventricular pacing by allowing intrinsic AV con-
duction (6). In our study, the rate of use of dual chamber
pacing was similar for all patients, regardless of the indica-
tion for pacing.
The shift in use to dual chamber technology likely reflects
improvements in lead and pacemaker design, as well as
results of clinical trials that highlight the benefits of atrial-
based pacing. Clinical trials comparing atrial-based with
ventricular-based pacing demonstrate that atrial-based pac-
ing prevents pacemaker syndrome, reduces the incidence of
atrial fibrillation, decreases the incidence of congestive heart
failure, improves quality of life, and reduces stroke (7–12).
Based on these trials, the American College of Cardiology/
American Heart Association/Heart Rhythm Society 2008
guidelines recommended dual-chamber pacing for the treat-
ment of symptomatic bradycardia in patients who were in
sinus rhythm and in whom atrioventricular synchrony and
rate responsiveness were desirable (13). This represents
most patients referred for cardiac pacing. Our observed shift
toward dual-chamber technology could be a response to
these clinical trials. Therefore, the National Coverage De-
termination for pacing, which emphasized single-chamber
pacing and was last modified in 1985, is not in line with
contemporary clinical practice.
Demographics of pacemaker patients. Pacemaker pa-
tients generally are elderly with associated medical comor-
bidities. Our study confirms that pacemakers are being
implanted later in life in patients with many medical
comorbidities. These findings are consistent with the
30-year study of pacemaker recipients in Olmstead
County, Minnesota, where the age adjusted CCI in-
creased from 3.15 to 4.60 (p  0.0001) (3). An increasing
CI value had an adverse effect on prognosis after
acemaker implantation.
mplantation trends: influence of health insurance and
ospital type. Pacemaker selection likely is influenced by
actors other than the patient’s age or associated medical
onditions. Lamas et al. (14) analyzed a cohort of pace-
aker recipients sampled from 20% of all Medicare bene-
ciaries over a 2-year period. Patients referred to large,
rban teaching hospitals were more likely to receive dual-
hamber pacemakers. In addition, Medicaid patients wereess likely to receive a dual-chamber pacemaker (odds ratio:
.78, 95% confidence interval: 0.71 to 0.86). Similarly, we
ound that type of insurance and implanting hospital impact
acemaker selection. The reasons for these disparities can-
ot be readily explained by our study.
inancial implications of pacemaker use. Finally, we
bserved that hospital charges are increasing, despite a
ecrease in the length of stay. Improvements in technology,
ften associated with dual-chamber pacing, come at a
igher cost. It is unclear whether these costs will continue to
ise and to what extent the healthcare system can withstand
his financial burden.
tudy limitations. The present analysis used the NIS,
hich is a national survey of hospital discharges and may
nderestimate total pacemaker implantation rate, because it
oes not capture outpatient procedures. In addition, the
IS suffers from the absence of clinical data. Nonetheless,
his large database represents national trends in hospitalized
atients.
onclusions
n summary, pacemaker implantation in the United
tates has increased over a 17-year period. Patients are
lder and have more medical comorbidities. The vast
ajority of pacemakers are dual-chamber pacemakers,
egardless of the indication for pacing. There are dispar-
ties in the use of dual-chamber pacing, based on the type
f hospital and insurance. The costs associated with
acemaker implantation are rising as well. These findings
ave important implications for future healthcare policy
ecisions.
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